Allogeneic hematopoietic cell transplantation (HCT) for treatment of hematological malignancies frequently fails because of disease recurrence. Attempts at intensifying the preparative regimen have been limited by associated toxicities due to the non-specific nature of most conditioning agents. The overall goal of Project 1 is to overcome this limitation by delivering targeted therapy to sites of leukemic involvement to decrease the risk of relapse after HCT without increased toxicity. We have shown that [131]l-anti-CD45 antibody (Ab; BCS) can deliver targeted radiation to hematopoietic tissues, with 2-3 times more radiation delivered to marrow, up to 12 times more to spleen, and 2- 8 times more to lymph nodes than to liver, lung or kidney. This observation has been translated to human studies that demonstrated the feasibility of combining [131]I- BC8 Ab with a reduced-intensity preparative regimen of fludarabine (FLU) and total body irradiation (TBI) in patients with advanced acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). We now propose three specific aims to extend these preliminary observations.
In Aim 1 we will perform a phase II study to define the efficacy of using [131]l-BC8 Ab combined with FLU and TBI in older patients with AML in remission.
In Aim 2 we will extend this approach to patients lacking HLA-matched donors by determining the maximally tolerated dose (MTD) of radiation delivered by [131]l-BC8 Ab that can be combined with a haplo-identical HCT strategy employing 2 Gy TBI, FLU, and cyclophosphamide. We will then conduct a phase II study of haplo-identical transplantation in order to estimate the efficacy of this regimen.
In Aim 3, we will build on our single-center experience by performing a multi-center phase I study to estimate the MTD of radiation that can be delivered via [90]Y-BC8 Ab when combined with FLU and 2 Gy TBI as a preparative regimen for older patients with advanced myeloid malignancies, and to determine the feasibility of exporting such a regimen to other institutions. We anticipate that these studies will eventually allow us to carry out definitive Phase III studies in which allogeneic HCT approaches employing [131]I- or [90]Y-BC8 Ab are compared to standard reduced-intensity and haplo-identical HCT methods. We are optimistic that these interventions will enhance the prognosis for patients with acute leukemias and myelodysplasia by increasing the response and survival rates, while minimizing toxicities.

Public Health Relevance

Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) currently kill the majority of affected patients despite treatment with chemotherapy and hematopoietic cell transplantation (HCT). In this project, we plan to target radiation therapy directly to the leukemia cells using a radiolabeled antibody for patients undergoing HCT with or without a matched donor (such as patients in ethnic minority groups). This could cure more patients and cause less toxicity than current therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA044991-25
Application #
8546157
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$264,637
Indirect Cost
$117,326
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-5
Orozco, Johnnie J; Kenoyer, Aimee; Balkin, Ethan R et al. (2016) Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood 127:352-9
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19
Chen, Robert; Gopal, Ajay K; Smith, Scott E et al. (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:1562-6
Graf, Solomon A; Gopal, Ajay K (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17:265-74
Green, D J; Bensinger, W I; Holmberg, L A et al. (2016) Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 51:1330-1336
Cassaday, Ryan D; Stevenson, Philip A; Gooley, Theodore A et al. (2015) High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. Br J Haematol 171:788-97
Cassaday, Ryan D; Storer, Barry E; Sorror, Mohamed L et al. (2015) Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant 21:281-7
Graf, S A; Stevenson, P A; Holmberg, L A et al. (2015) Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 26:2323-8
Frost, Sofia H L; Miller, Brian W; Bäck, Tom A et al. (2015) α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation. J Nucl Med 56:1766-73

Showing the most recent 10 out of 121 publications